Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach.
Endogenous prostaglandins (PGs) are involved in adaptive gastric protection against acute injury, and cyclooxygenase (COX)-1 is responsible for the production of PGs in this phenomenon. In the present study, we examined the effect of various COX inhibitors on gastric ulcerogenic and acid secretory responses following daily exposure of the stomach to iodoacetamide (IA) and investigated the role for COX isozyme in gastric protection under subchronic mucosal irritation. Gastric mucosal irritation was induced by addition of 0.1% IA to drinking water, and the gastric mucosa was examined on the 6th day. Indomethacin (5 mg/kg) or SC-560 (selective COX-1 inhibitor, 5 mg/kg) or rofecoxib (selective COX-2 inhibitor, 5 mg/kg) was given p.o. twice 24 hr and 3 hr before the termination of IA treatment. Giving IA in drinking water for 5 days produced minimal damage in the stomach. The damage was significantly worsened by indomethacin, resulting in hemorrhagic lesions. Both SC-560 and rofecoxib also aggravated such lesions, although the effect of rofecoxib was more pronounced. Treatment with IA decreased acid secretion in pylorus-ligated stomachs, and this change was significantly reverted by indomethacin as well as SC-560 and rofecoxib. Mucosal PGE2 content was increased following IA treatment, with apparent expression of COX-2 mRNA in the stomach, and the increased PGE2 production was significantly suppressed by SC-560 and rofecoxib as well as indomethacin. These results suggest that endogenous PGs derived from both COX-1 and COX-2 are involved in the mucosal defense of the inflamed stomach, partly by decreasing acid secretion and contribute to maintaining the mucosal integrity under such conditions.
Takeeda
M
M
Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto 607-8414, Japan.
Hayashi
Y
Y
Yamato
M
M
Murakami
M
M
Takeuchi
K
K
D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002211:Capsaicin / Q000008:administration & dosage / Q000009:adverse effects; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000737:chemistry / Q000494:pharmacology; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000502:physiology*; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D015870:Gene Expression / Q000187:drug effects; D007213:Indomethacin / Q000008:administration & dosage / Q000009:adverse effects; D007279:Injections, Subcutaneous; D007460:Iodoacetamide / Q000008:administration & dosage / Q000009:adverse effects; D007527:Isoenzymes / Q000009:adverse effects / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology / Q000502:physiology; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008565:Membrane Proteins; D009475:Neurons, Afferent / Q000187:drug effects; D011451:Prostaglandin-Endoperoxide Synthases / Q000009:adverse effects / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D013276:Stomach Ulcer / Q000139:chemically induced; D013450:Sulfones / Q000008:administration & dosage / Q000009:adverse effects; D014628:Vagotomy / Q000379:methods
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D011720:Pyrazoles; C115461:SC 560; D013450:Sulfones; C116926:rofecoxib; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; C496513:Ptgs1 protein, rat; D015232:Dinoprostone; D002211:Capsaicin; D007213:Indomethacin; D007460:Iodoacetamide